Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Molecular Mechanisms Underlying Abnormal Activation of T Cells in Idiopathic Aplastic Anemia and Hypoplastic Myelodysplastic Neoplasms

Zuzana Lenertová, Monika Kaisrlikova, David Kundrat, Hana Votavova, Jitka Vesela, Iva Trsová, Sarka Ransdorfova, Iuri Marinov, Tomas Prochazka, Daniel Lysak, Anna Jonasova, Jaroslav Čermák, Monika Belickova

Blood (2023) 142 (Supplement 1): 1342.

https://doi.org/10.1182/blood-2023-181713

Published: 2023

Journal Articles

Different Mutations in SF3B1 Gene Have Specific Transcriptomic Characteristics in Myelodysplastic Neoplasms

Iva Trsová, Andrea Hrustincova, Monika Belickova, Monika Kaisrlikova, Zuzana Lenertová, David Kundrat, Zdenek Krejcik, Jitka Vesela, Jaroslav Cermak, Anna Jonasova, Michaela Dostalova Merkerova

Blood (2023) 142 (Supplement 1): 3218.

https://doi.org/10.1182/blood-2023-179068

Published: 2023

Journal Articles

Aging-Related Gene Expression Signatures Define Likelihood of Disease Progression in Patients with Lower-Risk Myelodysplastic Syndromes

Monika Kaisrlikova, Iva Trsová, Zuzana Lenertova, Jitka Vesela, David Kundrat, Hana Votavova, Michaela Dostalova Merkerova, Zdenek Krejcik, Martin Vostry, Jaroslav Cermak, Monika Belickova

Blood (2022) 140 (Supplement 1): 4020–4021.

https://doi.org/10.1182/blood-2022-168503

Published: 2022

Journal Articles

Upregulation of ZEB1 -Derived Circular RNAs Is Associated with SF3B1 -Mutated Myelodysplastic Neoplasms

Iva Trsová, Monika Belickova, Andrea Hrustincova, Monika Kaisrlikova, Zuzana Lenertova, David Kundrat, Zdenek Krejcik, Jitka Vesela, Jiri Klema, Petr Ryšavý, Jaroslav Cermak, Michaela Dostalova Merkerova

Blood (2022) 140 (Supplement 1): 4005–4006.

https://doi.org/10.1182/blood-2022-159466

Published: 2022

Journal Articles

Risk Assessment in Patients with Myelodysplastic Neoplasms Using the Molecular International Prognostic Scoring System: A Single-Center Study from the Czech Republic

Jitka Vesela, Hana Votavova, Monika Kaisrlikova, Zuzana Lenertova, David Kundrat, Iva Trsová, Sarka Ransdorfova, Dana Mikulenkova, Jaroslav Cermak, Monika Belickova

Blood (2022) 140 (Supplement 1): 4098–4099.

https://doi.org/10.1182/blood-2022-165903

Published: 2022

Journal Articles

Circular RNAs in Myelodysplastic Syndromes and Impact of SF3B1 Mutations on Their Expression

Michaela Dostalova Merkerova, David Kundrat, Zdenek Krejcik, Andrea Hrustincova, Iva Trsova, Katarina Szikszai, Monika Kaisrlikova, Jitka Vesela, Jiri Klema, Jaroslav Cermak, Monika Belickova

Blood (2021) 138 (Supplement 1): 2590.

https://doi.org/10.1182/blood-2021-149633

Published: 2021

Journal Articles

Circulating Small Noncoding RNAs As Novel Semi-Invasive Markers of Patient Survival in Myelodysplastic Syndromes

Michaela Dostalova Merkerova, PhD MSc, Andrea Hrustincova, Zdenek Krejcik, David Kundrat, Katarina Szikszai, PhD, Jaroslav Cermak, Jitka Vesela, Monika Hruba, Monika Belickova, PhD

Blood (2019) 134 (Supplement_1): 3004.

https://doi.org/10.1182/blood-2019-126520

Published: 2019

Journal Articles

RUNX1 Mutation Accompanied with Dysregulated Cellular Senescence in Lower-Risk Myelodysplastic Syndrome Patients Is Associated with Disease Progression

Monika Hruba, Jitka Vesela, Hana Votavova, PhD, Michaela Dostalova Merkerova, PhD MSc, David Kundrat, Katarina Szikszai, PhD, Marie Lauermanova, MD, Zuzana Zemanova, PhD, Anna Jonasova, MD PhD, Jaroslav Cermak, MD PhD, Monika Belickova, PhD

Blood (2019) 134 (Supplement_1): 4230.

https://doi.org/10.1182/blood-2019-131150

Published: 2019

Journal Articles

Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms

Cristina Mambet, Olga Babosova, Jean-Philippe Defour, Emilie Leroy, Laura Necula, Oana Stanca, Aurelia Tatic, Nicoleta Berbec, Daniel Coriu, Monika Belickova, Barbora Kralova, Lucie Lanikova, Jitka Vesela, Christian Pecquet, Pascale Saussoy, Violaine Havelange, Carmen C. Diaconu, Vladimir Divoky, Stefan N. Constantinescu

Blood (2018) 132 (25): 2695–2699.

https://doi.org/10.1182/blood-2018-04-843060

Published: 2018

Includes: Supplemental data

Journal Articles

Relationship between Altered Gene Expression and DNA Methylation of the DLK1-DIO3 region in Azacitidine-Treated Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Myelodysplasia-Related Changes

Michaela Dostalova Merkerova, PhD MSc, Hana Remesova, Zdenek Krejcik, Nikoleta Loudova, Andrea Hrustincova, Katarina Szikszai, PhD, Jitka Vesela, MSc, Jaroslav Cermak, MD PhD, Anna Jonasova, MD, Monika Belickova, PhD

Blood (2018) 132 (Supplement 1): 5496.

https://doi.org/10.1182/blood-2018-99-113378

Published: 2018

Journal Articles

Deregulated Expression of Long Noncoding RNAs H19 , LEF1-AS1 , TCL6, and WT1-AS1 Predicts Poor Outcome of Patients with Myelodysplastic Syndromes

Michaela Dostalova Merkerova, PhD MSc, Nikoleta Loudova, Katarina Szikszai, PhD, Zdenek Krejcik, Jiri Klema, Pavla Pecherkova, Andrea Hrustincova, Jitka Vesela, MSc, Jaroslav Cermak, MD PhD, Anna Jonasova, MD, Monika Belickova, PhD

Blood (2018) 132 (Supplement 1): 5498.

https://doi.org/10.1182/blood-2018-99-116071

Published: 2018

Journal Articles

Mutations in RUNX1 and TP53 Genes Predict Progression in Patients with Lower-Risk Myelodysplastic Syndrome

Monika Hruba, MSc, Jitka Vesela, MSc, Hana Votavova, PhD, Michaela Dostalova Merkerova, PhD MSc, Katarina Szikszai, PhD, Marie Lauermannova, MD, Zuzana Zemanova, PhD, Anna Jonasova, MD, Jaroslav Cermak, MD PhD, Monika Belickova, PhD

Blood (2018) 132 (Supplement 1): 5519.

https://doi.org/10.1182/blood-2018-99-118048

Published: 2018

Journal Articles

Chromothripsis in High-Risk Myelodysplastic Syndromes: Incidence, Genetic Features, Clinical Implications, and Impact on Survival of Patients Treated with Azacytidine (Data from Czech MDS Group)

Zuzana Zemanova, PhD, Kyra Michalova, PhD, Karla Svobodova, Jana Brezinova, Halka Lhotska, PhD, Libuse Lizcova, PhD, Iveta Sarova, PhD, Silvia Izakova, Lucie Hodanova, PhD, Denisa Vesela, Sarka Ransdorfova, Monika Belickova, PhD, Jitka Vesela, MSc, Helena Polackova, Magda Siskova, MD, Radana Neuwirtova, MD PhD, Jaroslav Cermak, MD PhD, Tomas Stopka, MD PhD, Anna Jonasova, MD

Blood (2018) 132 (Supplement 1): 1815.

https://doi.org/10.1182/blood-2018-99-114151

Published: 2018

Journal Articles

Differential Expression of the Homologous Recombination DNA Repair Genes in Early and Advanced Stages of Myelodysplastic Syndrome

Jan Valka, MD, Jitka Vesela, Hana Votavova, PhD, Anna Jonasova, MD PhD, Jaroslav Cermak, MD PhD, Monika Belickova

Blood (2016) 128 (22): 5513.

https://doi.org/10.1182/blood.V128.22.5513.5513

Published: 2016

Journal Articles

Mutational Screening for Predictive Profiles of Progression in Myelodysplastic Syndrome

Monika Belickova, Jitka Vesela, Hana Votavova, PhD, Anna Jonasova, MD PhD, Jaroslav Cermak, MD PhD

Blood (2016) 128 (22): 1983.

https://doi.org/10.1182/blood.V128.22.1983.1983

Published: 2016

Journal Articles

Altered Expression of the Repair Genes in CD34+ Cells May be Responsible for Formation and Accumulation of Mutations in MDS Patients

Jan Valka, MD, Monika Belickova, Jitka Vesela, Eliska Stara, Barbora Pejsova, Anna Jonasova, MD PhD

Blood (2015) 126 (23): 4119.

https://doi.org/10.1182/blood.V126.23.4119.4119

Published: 2015

Journal Articles

Patterns of DNA Methylation and Gene Expression in Higher-Risk Myelodysplastic Syndromes: Predictors of Demethylating Therapy Response

Monika Belickova, Anna Jonasova, Jitka Vesela, Barbora Pejsova, Jiri Klema, Jaroslav Cermak

Blood (2015) 126 (23): 4803.

https://doi.org/10.1182/blood.V126.23.4803.4803

Published: 2015

Journal Articles

The Prognostic Significance of TP53 Mutations for Overall Outcome in Lower-Risk MDS Patients

Monika Belickova, Jitka Vesela, Anna Jonasova, MD, Eliska Stara, Barbora Planetova, Zuzana Zemanova, Jana Brezinova, Dana Mikulenkova, Jaroslav Cermak, MD PhD As. Prof.

Blood (2014) 124 (21): 4630.

https://doi.org/10.1182/blood.V124.21.4630.4630

Published: 2014

Journal Articles

Comparison of DNA Methylation and Expression Status Prior Azacytidine Treatment and their Relationship to Overall Survival and Clinical Response of MDS Patients

Monika Belickova, Anna T Jonasova, MD, Jitka Vesela, Eliska Stara, Andrea Hrustincova, Jaroslav Cermak, Ass. Prof., PhD

Blood (2013) 122 (21): 3777.

https://doi.org/10.1182/blood.V122.21.3777.3777

Published: 2013

Journal Articles

Changes in Gene Expression Profiles in Patients with 5q- Syndrome Caused by Lenalidomide Treatment

Monika Belickova, Jaroslav Cermak, Jitka Vesela, Eliska Cechova, Zuzana Zemanova, Kyra Michalova, PhD, Michaela Dostalova Merkerova, Anna Jonasova, MD

Blood (2011) 118 (21): 5023.

https://doi.org/10.1182/blood.V118.21.5023.5023

Published: 2011

NARROW

Molecular Mechanisms Underlying Abnormal Activation of T Cells in Idiopathic Aplastic Anemia and Hypoplastic Myelodysplastic Neoplasms

Different Mutations in SF3B1 Gene Have Specific Transcriptomic Characteristics in Myelodysplastic Neoplasms

Aging-Related Gene Expression Signatures Define Likelihood of Disease Progression in Patients with Lower-Risk Myelodysplastic Syndromes

Upregulation of ZEB1 -Derived Circular RNAs Is Associated with SF3B1 -Mutated Myelodysplastic Neoplasms

Risk Assessment in Patients with Myelodysplastic Neoplasms Using the Molecular International Prognostic Scoring System: A Single-Center Study from the Czech Republic

Circular RNAs in Myelodysplastic Syndromes and Impact of SF3B1 Mutations on Their Expression

Circulating Small Noncoding RNAs As Novel Semi-Invasive Markers of Patient Survival in Myelodysplastic Syndromes

RUNX1 Mutation Accompanied with Dysregulated Cellular Senescence in Lower-Risk Myelodysplastic Syndrome Patients Is Associated with Disease Progression

Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms

Relationship between Altered Gene Expression and DNA Methylation of the DLK1-DIO3 region in Azacitidine-Treated Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Myelodysplasia-Related Changes

Deregulated Expression of Long Noncoding RNAs H19 , LEF1-AS1 , TCL6, and WT1-AS1 Predicts Poor Outcome of Patients with Myelodysplastic Syndromes

Mutations in RUNX1 and TP53 Genes Predict Progression in Patients with Lower-Risk Myelodysplastic Syndrome

Chromothripsis in High-Risk Myelodysplastic Syndromes: Incidence, Genetic Features, Clinical Implications, and Impact on Survival of Patients Treated with Azacytidine (Data from Czech MDS Group)

Differential Expression of the Homologous Recombination DNA Repair Genes in Early and Advanced Stages of Myelodysplastic Syndrome

Mutational Screening for Predictive Profiles of Progression in Myelodysplastic Syndrome

Altered Expression of the Repair Genes in CD34+ Cells May be Responsible for Formation and Accumulation of Mutations in MDS Patients

Patterns of DNA Methylation and Gene Expression in Higher-Risk Myelodysplastic Syndromes: Predictors of Demethylating Therapy Response

The Prognostic Significance of TP53 Mutations for Overall Outcome in Lower-Risk MDS Patients

Comparison of DNA Methylation and Expression Status Prior Azacytidine Treatment and their Relationship to Overall Survival and Clinical Response of MDS Patients

Changes in Gene Expression Profiles in Patients with 5q- Syndrome Caused by Lenalidomide Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only